ArticleMolecular biology reports2025
Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebrolysin (CBL), a peptide derived from pig brain, is recognized for its neuroprotective and anti-inflammatory properties. This research aimed to investigate the effects of CBL on anxiety- and depression-like behaviors, spatial memory, the tryptophan/kynurenine (TRP/KYN) pathway, and inflammation in the prefrontal cortex (PFC) of a mouse model for schizophrenia. METHODS AND
resultsThirty-six male BALB/c mice were allocated into three experimental groups: control, ketamine (Ket) (20 mg/kg per day, i.p.), and Ket + CBL (2.5 mL/kg per day, i.p.). The open field test was used to evaluate anxiety-like behavior and locomotor activity, while the tail suspension test was used to assess depression-like behavior. Spatial memory was evaluated using the Lashley III Maze. Moreover, KYN and TRP levels were detected using an enzyme-linked immunosorbent assay. Inflammatory factors NLRP3 and IL-1β were assessed via the Western blot method. The results demonstrated that CBL administration significantly reduced anxiety-like behaviors, improved locomotor activity, decreased immobility time, and enhanced spatial learning and memory. Furthermore, CBL significantly lowered KYN levels and increased TRP levels in the PFC. Administration of Ket caused an increase in IL-1β levels. However, CBL did not significantly impact NLRP3 and IL-1β levels compared to the Ket group.
conclusionsThese findings demonstrate the neuroprotective properties of CBL, which are likely due to its modulatory action on the TRP/KYN pathway and improvement in spatial memory, anxiety, and depression-like behaviors in schizophrenia mice.
Indexed as
Identifiers
40668305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.